Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT04723940
Other study ID # JPAR 20D.1085
Secondary ID
Status Enrolling by invitation
Phase Phase 3
First received
Last updated
Start date January 25, 2021
Est. completion date January 25, 2023

Study information

Verified date January 2021
Source Rothman Institute Orthopaedics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Management of periprosthetic joint infection (PJI) commonly includes 6 weeks of intravenous (IV) antibiotics after surgical treatment. However, there is little evidence to suggest that oral (PO) therapy results in worse outcomes. This study aims to determine whether or not PO antibiotics are non-inferior to IV antibiotics in treating PJI. The study is a multicenter, parallel-group, randomized (1 : 1), open-label, non-inferiority trial. The non-inferiority margin will be set at 10%. Adults with a clinical diagnosis of PJI according to the International Consensus Meeting (ICM) criteria who would ordinarily receive at least 6 weeks of antibiotics and have received ≤ 7 days of IV therapy from surgery will be included. A total of 308 participants will be centrally computer-randomized to PO or IV antibiotics to complete the first 6 weeks of therapy. Follow-on PO therapy will be permitted in either arm. The primary outcome is the proportion of participants experiencing treatment failure within 1 year. An associated cost-effectiveness evaluation including complications, resource utilization and quality-of-life data will be performed.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 308
Est. completion date January 25, 2023
Est. primary completion date January 25, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - aged = 18 years - willing and able to give informed consent - primary THA or TKA diagnosed with PJI based on International Consensus Meeting criteria 1. A sinus communicating with the prosthesis OR 2. Two positive cultures obtained from the prosthesis OR 3. 3 of 5 criteria: - Elevated ESR (>30mm/hr) and CRP (>10mg/L) - Elevated synovial leukocyte count (>3000 cells/µL) or change of ++ on leukocyte esterase strip - Elevated synovial neutrophil percentage (>80%) - One positive culture - Positive histological analysis of periprosthetic tissue (>5 neutrophils per high power field in 5 high power fields x400) - PJI treated by debridement and implant retention, or excision of the prosthetic joint (with or without planned reimplantation) - received = 7 days of IV therapy after an appropriate surgical intervention Exclusion Criteria: - Previously treated for native septic arthritis or PJI in the same joint - S. aureus bacteremia on presentation or within the previous month - clinical, histological or microbiological evidence of mycobacterial, fungal or parasitic etiology of the infection - any other concomitant infection that, in the opinion of the clinician responsible for the patient, requires a prolonged course of IV antibiotic therapy (e.g. bacterial endocarditis, mediastinal infection, central nervous system infection) - septic shock or systemic features that, in the opinion of the clinician responsible for the patient, requires a course of IV antibiotic therapy (the patient could be re-evaluated if these features resolved) - an infection for which there are no suitable antibiotic choices to permit randomization between the two arms of the trial (e.g. when organisms are only sensitive to IV antibiotics or PO antibiotics) - unlikely to comply with trial requirements following randomization in the opinion of the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Bactrim
Bactrim will be given for 6 weeks to treat joint infection
Cefadroxil
Cefadroxil will be given for 6 weeks to treat joint infection
Doxycycline Hcl
Doxycycline HCl will given for 6 weeks to treat joint infection
Clindamycin
Clindamycin will given for 6 weeks to treat joint infection

Locations

Country Name City State
United States Rothman Orthopaedic Institute Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Rothman Institute Orthopaedics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of Postoperative Infections The investigator will measure the incidence of postoperative infections in participants treated with oral antibiotics versus those treated with intravenous antibiotics 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05519007 - Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone N/A
Active, not recruiting NCT04563325 - Oral-only Antibiotics for Bone and Joint Infections in Children Phase 4
Completed NCT05341908 - Prevalence of Pathogens in Synovial Fluid Obtained From Emergency Department Patients
Recruiting NCT03550911 - Biological Collection From Samples From The Gut Microbiota In Patients Having A Bone Or Joint Infection Treated By A Suppressive Subcutaneous Antibiotherapy With Betalactamine (CARBAMICROBIOTA)
Completed NCT04440631 - Gut Microbiome of Patients Undergoing Antibiotic Therapy for Orthopedic Device-related Infection
Recruiting NCT05753215 - Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection Phase 2
Recruiting NCT05137314 - Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA) Phase 1
Not yet recruiting NCT06293352 - Real-component vs All-cement Articulating Spacers for Periprosthetic Knee Infection N/A
Recruiting NCT04304885 - Effect of Sonication on Periprosthetic Joint Infection Treatment Strategy.
Completed NCT03403608 - Subcutaneous Suppressive Antibiotic Therapy for Bone and Joint Infections N/A
Recruiting NCT03704766 - Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis N/A
Completed NCT00974493 - Oral Versus Intravenous Antibiotics for Bone and Joint Infections (OVIVA B&J) Phase 4
Completed NCT03191292 - Bacterial Epidemiology and Empirical Antibiotherapy in Patients With Prosthetic Joint Infection N/A
Recruiting NCT06191601 - Interest in Probabilistic Antibiotic Therapy With Broad-spectrum Beta-lactams in Orthopedic Surgery
Completed NCT05804058 - Biofilm Composition as a Predictive Biomarker for Prosthetic Joint Infection
Completed NCT03426761 - Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections Phase 4
Enrolling by invitation NCT03713528 - Can Intraosseous Antibiotics Improve the Results of Irrigation & Debridement and Prosthetic Retention for PJI? Phase 4
Active, not recruiting NCT06402591 - Results of Extended Versus Single Dose Antibiotic Prophylaxis In Orthopedic Revision Arthroplasty in Nijmegen. Phase 3
Completed NCT04948281 - Joint Infection Following ACL Reconstruction
Completed NCT06267287 - Microbiological Structure of Pathogens of Periprosthetic Infection of Large Joints in the Post-Covid Period